![]() | |
Clinical data | |
---|---|
Trade names | Ravicti |
AHFS/ Drugs.com | Micromedex Detailed Consumer Information |
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
ChEMBL | |
CompTox Dashboard ( EPA) | |
ECHA InfoCard | 100.228.552 |
Chemical and physical data | |
Formula | C33H38O6 |
Molar mass | 530.661 g·mol−1 |
3D model ( JSmol) | |
| |
|
Glycerol phenylbutyrate, sold under the brand name Ravicti, is a medication used in the treatment of certain inborn urea cycle disorders. The medication works by preventing the harmful buildup of ammonia in the body. [3] It is an FDA-approved prescription drug in the US. [4] It was developed by Hyperion Therapeutics based on the existing medication sodium phenylbutyrate, and received approval in February 2013. [5]
Hyperion has been criticized for setting a high price for the drug. The price was set at US$250,000–290,000. In 2014, the drug generated $30.8 million in net sales, far behind the older and less expensive Buphenyl ($113.6 million in sales). [6]
![]() | |
Clinical data | |
---|---|
Trade names | Ravicti |
AHFS/ Drugs.com | Micromedex Detailed Consumer Information |
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
ChEMBL | |
CompTox Dashboard ( EPA) | |
ECHA InfoCard | 100.228.552 |
Chemical and physical data | |
Formula | C33H38O6 |
Molar mass | 530.661 g·mol−1 |
3D model ( JSmol) | |
| |
|
Glycerol phenylbutyrate, sold under the brand name Ravicti, is a medication used in the treatment of certain inborn urea cycle disorders. The medication works by preventing the harmful buildup of ammonia in the body. [3] It is an FDA-approved prescription drug in the US. [4] It was developed by Hyperion Therapeutics based on the existing medication sodium phenylbutyrate, and received approval in February 2013. [5]
Hyperion has been criticized for setting a high price for the drug. The price was set at US$250,000–290,000. In 2014, the drug generated $30.8 million in net sales, far behind the older and less expensive Buphenyl ($113.6 million in sales). [6]